Biogen Inc. (BIIB)

Stock Picks From Seeking Alpha's September 2026 New Analysts

Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says

Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Biogen's experimental lupus drug shows benefit against skin symptoms

Biogen's Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus

Biogen (NASDAQ:BIIB) Reaches New 12-Month High – Still a Buy?

Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?

4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day

Mesoblast (NASDAQ:MESO) and Biogen (NASDAQ:BIIB) Head-To-Head Contrast

Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN

Corient Private Wealth LP Raises Stock Holdings in Biogen Inc. $BIIB

Reviewing Fulcrum Therapeutics (NASDAQ:FULC) & Biogen (NASDAQ:BIIB)

LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer's Disease

Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience

Biogen Inc. (BIIB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology

Biogen (NASDAQ:BIIB) versus NewAmsterdam Pharma (NASDAQ:NAMS) Financial Analysis

Biogen Inc. (BIIB) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Lilly Builds Neuroscience into a New Long-Term Growth Driver